Beckman Coulter Pulls Out of Bidding War for Biosite, But Will Still Seek 'Content' Buys | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Beckman Coulter this week decided not to match a $92.50 per share bid by Inverness Medical Innovations to buy Biosite, effectively ending its plans to acquire the diagnostics firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.